KRAS - PDFSEARCH.IO - Document Search Engine

KRAS
Results: 659

#	Item
431	Medical Services Advisory Committee Public Summary Document Reference No. 44 – KRAS mutation testing for cetuximab (Erbitux®) Applicants: Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2013-11-01 01:33:24 KRAS Oncology Gastrointestinal cancer Colorectal cancer Cancer Metastasis Pharmaceutical Benefits Scheme Medicine Bristol-Myers Squibb Cetuximab
432	Advice to IPART concerning the calculations of metrics November 2014 Background: In 2012 Kanangra Ratings Advisory Services (KRAS) undertook some work for IPART concerning the financability of the regulated water network Add to Reading List Source URL: www.ipart.nsw.gov.au Language: English Financial statements Credit Leasing Fundamental analysis Debt Credit rating agency Financial ratio Earnings before interest taxes depreciation and amortization Cost of capital Finance Accountancy Business
433	Citation: Clinical and Translational Gastroenterology[removed], e62; doi:[removed]ctg[removed] & 2014 the American College of Gastroenterology All rights reserved 2155-384X/14 www.nature.com/ctg Mutant KRAS and GNAS DNA Add to Reading List Source URL: www.nature.com Language: English - Date: 2014-11-13 13:02:53 Gastroenterology Intraductal papillary mucinous neoplasm Pancreatic cancer Pancreatic duct Pancreatic disease Endoscopic retrograde cholangiopancreatography KRAS Secretin Chronic pancreatitis Medicine Pancreas disorders Anatomy
434	OPEN Citation: Cell Death and Disease[removed], e1260; doi:[removed]cddis[removed] & 2014 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddis Add to Reading List Source URL: www.nature.com Language: English - Date: 2014-05-29 08:44:58 Organic chemistry Non-small-cell lung carcinoma ERCC1 Gefitinib MicroRNA Epidermal growth factor receptor Erlotinib KRAS Cetuximab Chemistry Lung cancer Medicine
435	SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of Add to Reading List Source URL: www.scottishmedicines.org.uk Language: English Gastrointestinal cancer Cancer treatments Eli Lilly and Company Antifolates Pemetrexed Cetuximab Ustekinumab Psoriasis KRAS Medicine Oncology Lung cancer
436	60th MSAC Meeting 28 November 2013 PBAC referral relevant to Applications 1362 and 1363 – KRAS/RAS testing under MBS item[removed]for access to cetuximab/panitumumab Summary of consideration and rationale for MSAC’s ad Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-12-03 00:24:11 Cetuximab Biotechnology Panitumumab KRAS Oncogenes Immune system Colorectal cancer Ras subfamily Biomarker Medicine Biology Bristol-Myers Squibb
437	Pezsgés / Sparkling 0.15l Etyek-Buda Kras / SLO Champagne / FR Add to Reading List Source URL: baltazarbudapest.com Language: Hungarian - Date: 2014-10-16 05:12:54
438	60th MSAC Meeting 28 November[removed]PBAC referral relevant to Applications 1362 and 1363 – KRAS/RAS testing under MBS item[removed]for access to cetuximab/panitumumab Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-12-03 00:24:10 Cetuximab Biotechnology Panitumumab KRAS Oncogenes Immune system Colorectal cancer Ras subfamily Biomarker Medicine Biology Bristol-Myers Squibb
439	Medical Services Advisory Committee Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2013-11-01 01:33:24 KRAS Oncology Gastrointestinal cancer Colorectal cancer Cancer Metastasis Pharmaceutical Benefits Scheme Medicine Bristol-Myers Squibb Cetuximab
440	news Inside this issue • Cystic Fibrosis Investigations • 25-hydroxy Vitamin D • KRAS Testing Add to Reading List Source URL: www.pathologynorth.com.au Language: English - Date: 2013-01-14 21:15:57 Channelopathy Cystic fibrosis Pediatrics Sweat test Ivacaftor Epithelial sodium channel Cetuximab KRAS Congenital absence of the vas deferens Medicine Health Biology

UPDATE